Home » Stocks » Sierra Oncology

Sierra Oncology, Inc. (SRRA)

Stock Price: $12.42 USD 0.26 (2.14%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 129.11M
Revenue (ttm) n/a
Net Income (ttm) -108.74M
Shares Out 10.40M
EPS (ttm) -15.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $12.42
Previous Close $12.16
Change ($) 0.26
Change (%) 2.14%
Day's Open 12.16
Day's Range 12.16 - 12.42
Day's Volume 6,073
52-Week Range 8.55 - 22.00

More Stats

Market Cap 129.11M
Enterprise Value 6.14M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 10.40M
Float 4.84M
EPS (basic) -19.82
EPS (diluted) -15.27
FCF / Share -4.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9,529
Short Ratio 0.68
Short % of Float 0.20%
Beta 1.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.08
Revenue n/a
Operating Income -70.87M
Net Income -108.74M
Free Cash Flow -47.82M
Net Cash 122.97M
Net Cash / Share 11.83
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.27%
ROE -116.22%
ROIC 629.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$25.75*
(107.33% upside)
Low
17.0
Current: $12.42
High
33.0
Target: 25.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-66.99-55.42-42.62-48.08-35.83-22.58-4.01
Net Income-88.28-53.34-42.02-47.87-53.26-23.87-6.83
Shares Outstanding2.911.771.250.760.360.030.02
Earnings Per Share-30.30-30.16-33.68-63.20-1,258.80-2,763.20-767.20
Operating Cash Flow-51.18-45.12-36.16-41.16-28.27-21.79-3.57
Capital Expenditures-0.04-0.12-0.09-0.17-0.41-0.19-
Free Cash Flow-51.22-45.23-36.26-41.33-28.68-21.97-3.57
Cash & Equivalents14810610010915039.162.43
Total Debt0.374.89----0.41
Net Cash / Debt14710110010915039.162.02
Assets15110910211115340.572.46
Liabilities64.9814.997.477.737.404.011.76
Book Value86.3594.4894.73103145-108-34.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sierra Oncology, Inc.
Country Canada
Employees 71
CEO Stephen George Dilly

Stock Information

Ticker Symbol SRRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SRRA
IPO Date July 16, 2015

Description

Sierra Oncology researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.